Salbutamol ( DrugBank: Salbutamol )

---

8 diseases

ID	Disease name (Link within this page)	Number of trials
3	Spinal muscular atrophy	2
11	Myasthenia gravis	2
49	Systemic lupus erythematosus	2
85	Idiopathic interstitial pneumonia	1
86	Pulmonary arterial hypertension	2
111	Congenital myopathy	2
256	Muscle glycogenosis	1
299	Cystic fibrosis	6

3. Spinal muscular atrophy

---

Clinical trials : 237 /  Drugs : 123 - (DrugBank : 29) / Drug target genes : 51 - Drug target pathways : 75

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000041208	2020-12-30	2020-12-22	A randomized, double-blind, placebo parallel controlled clinical trial on the efficacy and safety of salbutamol sulfate tablets in the treatment of children with spinal muscular atrophy	A randomized, double-blind, placebo parallel controlled clinical trial on the efficacy and safety of salbutamol sulfate tablets in the treatment of children with spinal muscular atrophy	spinal muscular atrophy	experimental group: salbutamol sulfate tablets ;control group:placebo;	The Children's Hospital, Zhejiang University School of Medicine	NULL	Recruiting	2	17	Both	experimental group:60;control group:30;	Phase 4	China
2	EUCTR2007-001088-32-IT (EUCTR)	29/07/2008	18/07/2008	A PHASE II RANDOMIZED, DOUBLE-BLIND STUDY VS. PLACEBO FOR THE EVALUATION OF EFFICACY AND TOLERABILITY OF SALBUTAMOL ADMINISTERED BY ORAL ROUTE IN PATIENTS AFFECTED BY SPINAL MUSCULAR ATHROPHY. - ND	A PHASE II RANDOMIZED, DOUBLE-BLIND STUDY VS. PLACEBO FOR THE EVALUATION OF EFFICACY AND TOLERABILITY OF SALBUTAMOL ADMINISTERED BY ORAL ROUTE IN PATIENTS AFFECTED BY SPINAL MUSCULAR ATHROPHY. - ND	Patients affected by SMA MedDRA version: 9.1;Level: LLT;Classification code 10041582;Term: Spinal muscular atrophy	Trade Name: VOLMAX*30CPR 4MG R.P. INN or Proposed INN: Salbutamol	ISTITUTO NEUROLOGICO CARLO BESTA	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Italy

11. Myasthenia gravis

---

Clinical trials : 332 /  Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03914638 (ClinicalTrials.gov)	April 1, 2019	11/4/2019	Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis	Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis	Myasthenia Gravis	Drug: Salbutamol 4Mg Tablet;Drug: Placebo oral capsule	University of Aarhus	NULL	Recruiting	18 Years	N/A	All	30	Phase 2/Phase 3	Denmark
2	EUCTR2019-000895-40-DK (EUCTR)	28/03/2019	26/02/2019	Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis	Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis - BETA-MG	Myasthenia Gravis MedDRA version: 21.1;Level: PT;Classification code 10028417;Term: Myasthenia gravis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Salbutamol WZF 4 mg INN or Proposed INN: Salbutamol Other descriptive name: SALBUTAMOL SULFATE PH. EUR.	Aarhus University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 3	Denmark

49. Systemic lupus erythematosus

---

Clinical trials : 993 /  Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-004635-29-DK (EUCTR)	09/11/2007	02/10/2007	Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301	Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301	Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions of the skin can also be included in the study.	Product Name: ASF-1096 Cream 0.25% INN or Proposed INN: R-salbutamol sulphate Product Name: ASF-1096 Cream 0.5% INN or Proposed INN: R-salbutamol sulphate Product Name: ASF-1096 Cream 1.0% INN or Proposed INN: R-salbutamol sulphate	Astion Pharma A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140		Denmark;Spain;Sweden
2	EUCTR2007-004635-29-SE (EUCTR)	07/11/2007	12/09/2007	Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301	Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301	Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions of the skin can also be included in the study.	Product Name: ASF-1096 Cream 0.25% INN or Proposed INN: R-salbutamol sulphate Product Name: ASF-1096 Cream 0.5% INN or Proposed INN: R-salbutamol sulphate Product Name: ASF-1096 Cream 1.0% INN or Proposed INN: R-salbutamol sulphate	Astion Pharma A/S	NULL	Not Recruiting			Female: yes Male: yes	140		Denmark;Spain;Sweden

85. Idiopathic interstitial pneumonia

---

Clinical trials : 627 /  Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01457261 (ClinicalTrials.gov)	April 2012	19/10/2011	IPF Drug Deposition Study	A Study of the Pharmacokinetics and Deposition of Inhaled Salbutamol in Patients With Idiopathic Pulmonary Fibrosis (TOPICAL-IPF)	Idiopathic Pulmonary Fibrosis	Drug: Salbutamol	Royal Brompton & Harefield NHS Foundation Trust	GlaxoSmithKline	Completed	40 Years	N/A	Both	10	Phase 1	United Kingdom

86. Pulmonary arterial hypertension

---

Clinical trials : 1,205 /  Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02782052 (ClinicalTrials.gov)	July 2016	17/5/2016	Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension	Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Nebulized ipratropium bromide;Drug: Nebulized combination ipratropium bromide with salbutamol;Drug: Nebulized Placebo	Assistance Publique - Hôpitaux de Paris	NULL	Withdrawn	18 Years	N/A	All	0	Phase 3	NULL
2	EUCTR2014-002590-10-FR (EUCTR)	11/02/2016	02/03/2016	Effect of bronchodilators on effort induced dyspnoea in lung hypertension patients	Effect of bronchodilators on effort induced dyspnoea in patients suffering lung hypertension - BD-HTAP	Idiopathic or heritable patients with pulmonary arterial hypertension (PAH). MedDRA version: 18.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: Bromure d'Ipratropium Product Name: Bromure d'Ipratropium INN or Proposed INN: Bromure d'Ipratropium Trade Name: Salbutamol Product Name: Salbutamol INN or Proposed INN: Salbutamol	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Not Recruiting			Female: yes Male: yes	18	Phase 3	France

111. Congenital myopathy

---

Clinical trials : 10 /  Drugs : 17 - (DrugBank : 5) / Drug target gene : 1 - Drug target pathways : 9

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05099107 (ClinicalTrials.gov)	October 25, 2021	15/10/2021	Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment	COMPIS- Congenital Myopathy Intervention Study. An Open-label, Cross Over, Randomised, Controlled Study Using Oral Salbutamol	Congenital Myopathy;Neuromuscular Diseases;Musculoskeletal Diseases;Nemaline Myopathy;Centronuclear Myopathy;Myosin Storage Myopathy	Drug: Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet;Drug: Salbutamol Only Product in Oral Dose Form	Vastra Gotaland Region	NULL	Enrolling by invitation	6 Years	30 Years	All	20	N/A	Sweden
2	EUCTR2019-001147-51-SE (EUCTR)	31/03/2020	27/09/2019	This is a treatment study for a muscle disorder known as congenital myopathy	Congenital myopathy intervention study - COMPIS	Congenital myopathy MedDRA version: 20.0;Level: PT;Classification code 10062547;Term: Congenital myopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Ventoline tablet 2mg INN or Proposed INN: SALBUTAMOL SULFATE Trade Name: Ventoline oral solution 0,4mg/ml INN or Proposed INN: SALBUTAMOL SULFATE	Västra götalandsregionen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 4	Sweden

256. Muscle glycogenosis

---

Clinical trials : 180 /  Drugs : 133 - (DrugBank : 29) / Drug target genes : 25 - Drug target pathways : 105

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02405598 (ClinicalTrials.gov)	October 2013	22/3/2015	Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease	Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease	Pompe Disease	Drug: Salbutamol	National Taiwan University Hospital	NULL	Completed	2 Years	N/A	Both	14	Phase 4	Taiwan

299. Cystic fibrosis

---

Clinical trials : 1,695 /  Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-004068-24-IT (EUCTR)	21/05/2021	02/08/2021	Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis	A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 52-Week, Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Non-Cystic Fibrosis Bronchiectasis (MAHALE) - MAHALE	Non-cystic fibrosis bronchiectasis (NCFB) MedDRA version: 20.0;Level: SOC;Classification code 10038738;Term: Respiratory, thoracic and mediastinal disorders;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Trade Name: NA Product Name: benralizumab Product Code: [MEDI-563] INN or Proposed INN: benralizumab Other descriptive name: benralizumab Product Name: Atropina Product Code: [NA] Product Name: Antistaminici H1 - H2 Product Code: [na] Product Name: C01CA04 - Dopamina Product Code: [na] Product Name: Adrenalina Product Code: [NA] Product Name: Salbutamolo Product Code: [NA] Product Name: H02 - Corticosteroidi Sistemici Product Code: [NA]	ASTRAZENECA AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	420	Phase 3	United States;Philippines;Spain;Russian Federation;United Kingdom;Italy;India;Vietnam;Canada;Argentina;Poland;Australia;Denmark;Germany;China;Korea, Republic of
2	EUCTR2016-004558-13-IT (EUCTR)	19/10/2020	21/10/2020	A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasischronically infected with Pseudomonas aeruginosa (P. aeruginosa)	A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasischronically infected with Pseudomonas aeruginosa (P. aeruginosa) - Promis II	Non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa MedDRA version: 21.0;Level: PT;Classification code 10006445;Term: Bronchiectasis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]	Trade Name: Promixin Product Name: Colistimethate sodium Product Code: [NA] Other descriptive name: Colistimethate Sodium Trade Name: Salbutamol-ratiopharm® N metered-dose aerosol inhaler Product Name: Salbutamol-ratiopharm® N metereddose aerosol inhaler Product Code: [Salbutamol] INN or Proposed INN: SALBUTAMOL Other descriptive name: Salbutamol	ZAMBON SPA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	420	Phase 3	Portugal;United States;France;Greece;Canada;Argentina;Poland;Germany;Italy
3	NCT03522831 (ClinicalTrials.gov)	May 1, 2018	19/3/2018	CF Bronchodilation	A Double-blind Placebo-controlled Crossover Study to Assess the Effects of Bronchodilation on Dyspnea, Ventilatory Responses, and Exercise Tolerance in Adults With Cystic Fibrosis	Lung Diseases;Cystic Fibrosis	Drug: Salbutamol;Drug: Placebo	University of British Columbia	NULL	Active, not recruiting	19 Years	N/A	All	20	N/A	Canada
4	EUCTR2015-002743-33-IT (EUCTR)	02/03/2017	25/01/2021	A double-blind, placebo-controlled, multi-centre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)	A double-blind, placebo-controlled, multi-centre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa) - Promis 1	Non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa MedDRA version: 21.0;Level: PT;Classification code 10006445;Term: Bronchiectasis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]	Trade Name: Promixin/Tadim Product Name: Colistimethate sodium Product Code: [-] INN or Proposed INN: COLISTIMETHATE SODIUM Other descriptive name: - Trade Name: Ventolin¿ Evohaler¿ Product Name: Ventolin Product Code: [Ventolin] INN or Proposed INN: SALBUTAMOL Other descriptive name: Ventolin® Evohaler	ZAMBON SPA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	420	Phase 3	Portugal;Greece;Spain;Israel;Italy;Switzerland;United Kingdom;France;Belgium;Australia;Germany;Netherlands;New Zealand
5	EUCTR2015-001317-28-NL (EUCTR)	30/07/2015	19/05/2015	A B2-agonist as a CFTR activator in CF - Part 2	A B2-agonist as a CFTR activator in CF - Part 2 - ABBA 2	Cystic fibrosis;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Salbutamol	UMC Utrecht	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Netherlands
6	EUCTR2014-000057-37-NL (EUCTR)	30/04/2014	12/02/2014	Bronchodilcation as a CFTR activator in CF	A B2-agonist as a CFTR activator in CF - ABBA study	Cystic Fibrosis;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]	Product Name: Salbutamol Product Code: R03AC02 INN or Proposed INN: SALBUTAMOL Product Name: Salbutamol Product Code: R03CC02 INN or Proposed INN: SALBUTAMOL	University Medical Centre Utrecht	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Netherlands

Back to top